<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31762">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02693197</url>
  </required_header>
  <id_info>
    <org_study_id>T817MAUS113</org_study_id>
    <nct_id>NCT02693197</nct_id>
  </id_info>
  <brief_title>PK Study of T-817 in Subjects With Hepatic Impairment</brief_title>
  <official_title>A Phase 1, Two-Part, Open-Label, Parallel-Cohort, Single-Dose Study to Determine the Pharmacokinetics of T-817MA in Adult Subjects With Hepatic Impairment and in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Toyama Chemical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Toyama Chemical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The primary objective is to determine the single-dose pharmacokinetics (PK) of T-817 and
      T-817M5 (metabolite of T-817) in subjects with mild, moderate or severe hepatic impairment
      compared to matched healthy control subjects.

      The secondary objective is to determine the safety and tolerability of single-dose T -817MA
      (Maleate salt of T-817) in subjects with mild, moderate or severe hepatic impairment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2016</start_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve (AUC)</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach the maximum observed plasma concentration (tmax)</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination rate constant</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination half-life (t½)</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total plasma clearance of unbound drug after oral (extravascular) administration (CL/F)</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution during the terminal elimination phase after oral (extravascular) administration (Vd/F)</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite to parent ratio (MPR)</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>8days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Cohort 1:T-817MA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild hepatic impairment subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2:T-817MA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects matched to subjects in Cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3:T-817MA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate hepatic impairment subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4:T-817MA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects matched to subjects in Cohort 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 :T-817MA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe hepatic impairment subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6:T-817MA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects matched to subjects in Cohort 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T-817MA</intervention_name>
    <description>A single oral dose of 448 mg</description>
    <arm_group_label>Cohort 1:T-817MA</arm_group_label>
    <arm_group_label>Cohort 2:T-817MA</arm_group_label>
    <arm_group_label>Cohort 3:T-817MA</arm_group_label>
    <arm_group_label>Cohort 4:T-817MA</arm_group_label>
    <arm_group_label>Cohort 5 :T-817MA</arm_group_label>
    <arm_group_label>Cohort 6:T-817MA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For subjects with mild, moderate or severe hepatic impairment

          1. Adult male or female, 18 - 75 years of age

          2. Must weigh at least 50 kg and have a body mass index (BMI) ≥ 18.5 and ≤ 40.0 kg/m2

          3. Have mild, moderate or severe defined by Child-Pugh classification hepatic impairment

        For Matched Healthy Control Subjects Healthy adult male or female subjects will be matched
        1:1 to a specific subject in the mild, moderate, or severe hepatic impairment cohort based
        upon age, weight, gender, and smoking status

        Exclusion Criteria:

          1. Subject is mentally or legally incapacitated or has significant emotional problems at
             the time of the screening visit or expected during the conduct of the study.

          2. History or presence of clinically significant medical or psychiatric condition or
             disease in the opinion of the PI.

          3. History or presence of hypersensitivity or idiosyncratic reaction to the study drug,
             related compounds, or inactive ingredients.

          4. Female subjects who are pregnant or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Preston, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Marbury, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orlando Clinical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>September 9, 2016</lastchanged_date>
  <firstreceived_date>January 26, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
